MGF
Research onlyAlso known as: RefChem:1100420, CHEBI:49739, Trifluoromagnesate(1-), TRIFLUOROMAGNESATE, SCHEMBL29386712
MGF (RefChem:1100420, CHEBI:49739, Trifluoromagnesate(1-)) is classified under igf & growth-factor peptides, sold for research use only and not approved for human consumption.
Read the full guide: what the research shows on MGF →What the research says
Aggregated from the cited literature below. We summarize sources — we don't author claims.
In the provided sources, “MGF” is described in multiple experimental contexts as mechano growth factor (MGF) and/or an MGF E peptide (often focusing on MGF E-domain peptides such as T-MGF-19E or MGF E peptide). Research investigated MGF/MGF E peptides in preclinical models of bone repair (including osteoblast/BMSC responses and rabbit injury/rupture models), and in cell-based settings related to apoptosis/angiogenesis in anterior cruciate ligament (ACL) repair.
Mechanism (as reported)
A mechanistic theme across the provided studies is that MGF or MGF E peptide can influence cell survival and differentiation pathways under hypoxic conditions. Reported pathways/components include HIF-1α regulation and apoptosis signaling (including caspase-related measurements) as well as signaling pathway involvement such as MEK-ERK1/2 and PI3K-Akt. (PMIDs: 30317597, 28927682, 24908137)
Key findings (each cites a source)
- A study reported that MGF-19E (an MGF E peptide variant) promoted proliferation, differentiation, and mineralization of MC3T3-E1 osteoblast cells, and that a rabbit bone defect model showed improved bone injury healing after candidate MGF E peptide treatment, with T-MGF-19E described as showing particularly significant effects on mineralization in vitro. [PMID 32339623]
- Research reported that MGF E peptide protected ACL fibroblasts against hypoxia-induced apoptosis, associated with effects on HIF-1α expression and apoptosis-related caspase and protein measurements, and that implicated pathways included MEK-ERK1/2 and PI3K-Akt; the same study reported effects in a rabbit ACL rupture model (including decreased HIF-1α expression, reduced apoptosis, and facilitated cell proliferation) and reported accelerated angiogenesis associated with an SDF-1α/CXCR4 axis and increased VEGF-α expression level. [PMID 30317597]
- A study reported that MGF E peptide pretreatment improved proliferation and osteogenic differentiation of BMSCs under severe hypoxia (simulated with CoCl2), with reported inhibition of HIF-1α expression/translocation and involvement of MEK-ERK1/2 and PI3K-Akt signaling; the study also reported that short-time treatment with MGF E peptide alone promoted osteogenic differentiation. [PMID 28927682]
- A study reported that PEGDMA hydrogel microrods loaded with MGF peptide achieved sustained delivery (measured as delivery for about 2 weeks) and showed increased migration of human mesenchymal stem cells; the study also reported reduced apoptosis in neonatal rat ventricular myocytes under hypoxia as assessed by TUNEL and increased Bcl-2 expression, while microrods without MGF were also reported to affect cytoskeleton/adhesion/proliferation of hMSCs. [PMID 24908137]
Independent test grades
No independent third-party test data is available for MGF yet. Our test grades are aggregated from Finnrick, which independently tests a subset of research peptides — many approved drugs and newer or niche compounds aren't covered.
Research literature (9)
Consolidated from PubMed — each links to the original record.
- The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease.
Rossing P, Baeres FMM, Bakris G, Bosch-Traberg H, Gislum M, Gough SCL · Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2023 · PMID 36651820
- Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial.
Stratigos AJ, Sekulic A, Peris K, Bechter O, Prey S, Kaatz M · The Lancet. Oncology · 2021 · PMID 34000246
- MGF-19E peptide promoted proliferation, differentiation and mineralization of MC3T3-E1 cell and promoted bone defect healing.
Wei W, Liu S, Song J, Feng T, Yang R, Cheng Y · Gene · 2020 · PMID 32339623
- MGF E peptide improves anterior cruciate ligament repair by inhibiting hypoxia-induced cell apoptosis and accelerating angiogenesis.
Sha Y, Yang L, Lv Y · Journal of cellular physiology · 2019 · PMID 30317597
- Glucose-Dependent Insulinotropic Polypeptide Receptor-Expressing Cells in the Hypothalamus Regulate Food Intake.
Adriaenssens AE, Biggs EK, Darwish T, Tadross J, Sukthankar T, Girish M · Cell metabolism · 2019 · PMID 31447324
- MGF E peptide pretreatment improves the proliferation and osteogenic differentiation of BMSCs via MEK-ERK1/2 and PI3K-Akt pathway under severe hypoxia.
Sha Y, Lv Y, Xu Z, Yang L, Hao X, Afandi R · Life sciences · 2017 · PMID 28927682
FAQ
- What is MGF?
- MGF (RefChem:1100420, CHEBI:49739, Trifluoromagnesate(1-)) is classified under igf & growth-factor peptides, sold for research use only and not approved for human consumption. Research goals associated with it include recovery & tissue repair, body composition & muscle.
- Is MGF FDA-approved?
- No. MGF is sold for research use only and is not approved for human consumption.
- What does the research on MGF say?
- peptideone aggregates 9 references from PubMed for MGF. The summary on this page digests them with citations; we summarize sources and make no efficacy claims.